Autolus Therapeutics (AUTL) Asset Writedowns and Impairment (2023 - 2025)

Autolus Therapeutics' Asset Writedowns and Impairment history spans 3 years, with the latest figure at -$7.2 million for Q4 2025.

  • For Q4 2025, Asset Writedowns and Impairment fell 1646.38% year-over-year to -$7.2 million; the TTM value through Dec 2025 reached -$7.6 million, changed N/A, while the annual FY2025 figure was $349000.0, N/A changed from the prior year.
  • Asset Writedowns and Impairment reached -$7.2 million in Q4 2025 per AUTL's latest filing, down from -$414000.0 in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $414000.0 in Q2 2024 to a low of -$7.2 million in Q4 2025.
  • Average Asset Writedowns and Impairment over 3 years is -$1.7 million, with a median of -$16000.0 recorded in 2023.
  • The largest YoY upside for Asset Writedowns and Impairment was 1646.38% in 2025 against a maximum downside of 1646.38% in 2025.
  • A 3-year view of Asset Writedowns and Impairment shows it stood at $382000.0 in 2023, then plummeted by 208.38% to -$414000.0 in 2024, then plummeted by 1646.38% to -$7.2 million in 2025.
  • Per Business Quant, the three most recent readings for AUTL's Asset Writedowns and Impairment are -$7.2 million (Q4 2025), -$414000.0 (Q4 2024), and $414000.0 (Q2 2024).